Purpose BRAF V600E mutation is seen in 5% to 8% of patients with metastatic colorectal
cancer (CRC) and is associated with poor prognosis. Vemurafenib, an oral BRAF V600 …

The world of molecular profiling has undergone revolutionary changes over the last few
years as knowledge, technology, and even standard clinical practice have evolved. Broad …

Colorectal cancer (CRC) is a leading cause of death among cancer patients. This
heterogeneous disease is characterized by alterations in multiple molecular pathways …

Sporadic colorectal cancer (CRC) is a somatic genetic disease in which pathogenesis is
influenced by the local colonic environment and the patient's genetic background …

Opinion statement TNM stage remains the key determinant of patient prognosis after
surgical resection of colorectal cancer (CRC), and informs treatment decisions. However …

Background: The prognostic value of BRAF and KRAS mutations within microsatellite-
unstable (MSI) and microsatellite-stable (MSS) subgroups of resected colon carcinoma …

Cytokine networks are crucial aspects of tumour immunology, particularly for colorectal
cancer (CRC), in which inflammation and antitumour immunity are key determinants of …

In patients with colorectal cancer (CRC) that metastasizes to the liver, there are several key
goals for improving outcomes including early detection, effective prognostic indicators of …

Due to differences in anatomy, primary rectal and colon cancer require different staging
procedures, different neo-adjuvant treatment and different surgical approaches. For …

Background Precision cancer medicine depends on defining distinct tumour subgroups
using biomarkers that may occur at very modest frequencies. One such subgroup comprises …